logo
  

Adaptive Biotech Launches ClonoSEQ Assay To Detect Diffuse Large B-cell Lymphoma

Adaptive Biotechnologies Corp. (ADPT) Thursday announced the launch of its clonoSEQ Assay to detect minimal residual disease in blood for patients with diffuse large B-cell lymphoma or DLBCL.

The commercial-stage biotechnology company said clonoSEQ can assess a patient's MRD status in DLBCL by measuring ctDNA, the fragments of DNA released into the blood from dying cancer cells.

Through the test, clinicians can make a sensitive and quantitative assessment of disease burden and can detect relapse and advise a precise treatment plan.
DLBCL is a non-Hodgkin lymphoma affecting more than 100,000 people in the U.S.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
RELATED NEWS
Follow RTT